ClinicalTrials.gg
CompletedNCT04347005Updated Nov 16, 2020

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

A Phase 1 interventional study of Cohort 1: AR882 and Cohort 2: AR882 in Healthy Volunteers, sponsored by Arthrosi Therapeutics. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-16.

Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2019, 7 years 3 months ago, and no results have been posted to the registry.
  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2019, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in healthy adult males.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum uric acid level ≥ 4.5 mg/dL (268 µmol/L)
  • Body weight no less than 50 kg and (BMI) within the range of ≥18 and ≤33 kg/m2
  • Must be free of any disease that requires a physician's care and/or would interfere with study evaluations or procedures

Exclusion criteria

Exclusion Criteria:

  • within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
  • History of cardiac abnormalities
  • History and/or presence of drug addiction or excessive use of alcohol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    AR882 (Dose A)

    Drug: Cohort 1: AR882

  • Experimental
    AR882 (Dose B)

    Drug: Cohort 2: AR882 · Drug: Cohort 6: AR882 Food Effect · Drug: Cohort 8: AR882 in combination with allopurinol · Drug: Cohort 9: AR882 in combination with febuxostat

  • Experimental
    AR882 (Dose C)

    Drug: Cohort 3: AR882

  • Experimental
    AR882 (Dose D)

    Drug: Cohort 4: AR882

  • Experimental
    AR882 (Dose E)

    Drug: Cohort 5: AR882

  • Experimental
    AR882 (Dose B) Solid Oral Formulation

    Drug: Cohort 7: AR882 Solid Oral Formulation

  • Placebo comparator
    Placebo

    Drug: Cohort 1: AR882 · Drug: Cohort 2: AR882 · Drug: Cohort 3: AR882 · Drug: Cohort 4: AR882 · Drug: Cohort 5: AR882 · Drug: Cohort 6: AR882 Food Effect · Drug: Cohort 7: AR882 Solid Oral Formulation

  • Active comparator
    Allopurinol

    Drug: Cohort 8: AR882 in combination with allopurinol

  • Active comparator
    Febuxostat

    Drug: Cohort 9: AR882 in combination with febuxostat

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findings

    Analysis of abnormal safety laboratory findings

    Time frame: 8 Days

  2. Safety Analyses

    ECG Heart Rate

    Time frame: 8 Days

  3. Safety Analyses

    ECG PR-Interval

    Time frame: 8 Days

  4. Safety Analyses

    ECG RR-Interval

    Time frame: 8 Days

  5. Safety Analyses

    ECG QRS-Interval

    Time frame: 8 Days

  6. Safety Analyses

    ECG QT-Interval

    Time frame: 8 Days

  7. Safety Analyses

    ECG QTc-Interval

    Time frame: 8 Days

  8. Safety Analyses

    Vital Sign - Systolic Blood Pressure

    Time frame: 8 Days

  9. Safety Analyses

    Vital Sign - Diastolic Blood Pressure

    Time frame: 8 Days

  10. Safety Analyses

    Vital Sign - Pulse Rate

    Time frame: 8 Days

  11. Safety Analyses

    Vital Sign - Body Temperature

    Time frame: 8 Days

  12. Safety Analyses

    Vital Sign - Respiratory Rate

    Time frame: 8 Days

  13. Area under the curve (AUC) for plasma AR882

    Profile from plasma in terms of AUC for AR882

    Time frame: 6 Days

  14. Time to maximum plasma concentration (Tmax) for AR882

    Profile from plasma in terms of Tmax for AR882

    Time frame: 6 Days

  15. Maximum plasma concentration (Cmax) for AR882

    Profile from plasma in terms of Cmax for AR882

    Time frame: 6 Days

  16. Apparent terminal half-life (t1/2) for AR882

    Profile from plasma in terms of t1/2 for AR882

    Time frame: 6 Days

  17. Amount excreted (Ae) into urine for AR882

    Profile from urine in terms of Ae for AR882

    Time frame: 6 Days

  18. Fractional Excretion (FEUA) for AR882

    Profile from urine in terms of FEUA for AR882

    Time frame: 6 Days

Secondary outcomes

  1. PD profile of a single dose of AR882

    Profile from serum uric acid concentrations over time

    Time frame: 6 Days

  2. PD profile of a single dose of AR882 in combination with allopurinol

    Profile from serum uric acid concentrations over time

    Time frame: 6 Days

  3. PD profile of a single dose of AR882 in combination with febuxostat

    Profile from serum uric acid concentrations over time

    Time frame: 6 Days

07

Study locations

1 site
  • Nucleus Network Pty, Ltd.
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jul 2019, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2020
First posted
Apr 15, 2020
StartActual
Jan 22, 2019
Primary completionActual
Jul 31, 2019
CompletionActual
Jul 31, 2019
Last update
Nov 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04347005
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Jan 22, 2019
Primary completion
Jul 31, 2019
Completion
Jul 31, 2019
Last update
Nov 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AR882 · Allopurinol · Febuxostat

Start the discussion